全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...
-  2017 

进行性核上性眼肌麻痹的诊疗进展 Diagnosis and Treatment Progress of Progressive Supranuclear Palsy

Keywords: 核上性眼肌麻痹,进行性,发病机制,诊断,治疗

Full-Text   Cite this paper   Add to My Lib

Abstract:

进行性核上性眼肌麻痹(PSP)是一种罕见的神经系统变性疾病,临床表现多样,容易和多种疾病混淆,诊断是临床医生的难点。最近国际上关于PSP治疗的几个最新的大型临床试验研究已经结束,为其治疗的临床研究带来了新的希望。本文就PSP的诊断、最新的治疗进展作一综述

References

[1]  Massey LA,Micallef C,Paviour DC,et al.Conventional magnetic resonance imaging in confirmed progressive supranuclear palsy and multiple system atrophy[J].Mov Disord,2012,27(14),1 754-1 762.
[2]  Leiguarda RC,Pramstaller PP,Merello M,et al.Apraxia in Parkinson’s disease,progressive supranuclear palsy,multiple system atrophy and neuroleptic-induced parkinsonism[J].Brain,1997,120:75-90.
[3]  Golbe LI,Davis PH,Schoenberg BS,et al.Prevalence and natural history of progressive supranuclear palsy[J].Neurology,1988,38(7):1 031-1 034.
[4]  Litvan I,Mangone CA,McKee A,et al.Natural history of progressive supranuclear palsy(Steele-Richardson-Olszewski syndrome)and clinical predictors of survival:a clinicopathological study[J],Neurol Neurosurg Psychiatry,1996,60:615-620.
[5]  Chiu WZ,Kaat LD,Seelaar H,et al.Survival in progressive supranuclear palsy and frontotemporal dementia[J].J Neurol Neurosurg Psychiatry,2010,81(4):441-445.
[6]  O’Sullivan SS,Massey LA,Williams DR,et al.Clinical outcomes of progressive supranuclear palsy and multiple system atrophy[J].Brain,2008,131(Pt 5):1 362-1 372.
[7]  dell’Aquila C,Zoccolella S,Cardinali V,et al.Predictors of survival in a series of clinically diagnosed progressive supranuclear palsy patients[J].Parkinsonism Relat Disord,2013,19(11):980-985.
[8]  Arena JE,Weigand SD,Whitwell JL,et al.Progressive supranuclear palsy:progression and survival[J].Neurology,2016,263(2):380-389.
[9]  Colosimo C,Bak TH,Bologna M,et al.Fifty years of progressive supranuclear palsy[J].J Neurol Neurosurgy Psychiatry,2014,85(8):938-944.
[10]  Zhao Y,Tseng IC,Heyser CJ,et al.Appoptosin-Mediated caspase cleavage of Tau contributes to progressive supranuclear palsy pathogenesis[J].Neuron,2015,87:963-975.
[11]  Respondek G,Hoglinger GU.The phenotypic spectrum of progressive supranuclear palsy[J],Parkinsonism Relat Disord,2016,22(1):S34-S36.
[12]  Mascalchi M,Vella A,Ceravolo R.Movement disorders:role of imaging in diagnosis[J].J Magn Reson Imaging,2012,35(2):239-256.
[13]  Van Balken I,Litvan I.Current and future treatments in progressive supranuclear palsy[J].Curr Treat Options Neurol,2006,8:211-223.
[14]  Stamelou M,de Silva R,Arias-Carrión O,et al.Rational therapeutic approaches to progressive supranuclear palsy[J].Brain J Neurol,2010,13(3):1 578-1 590.
[15]  Litvan I.Diagnosis and management of progressive supranuclear palsy[J].Semin Neurol,2001,1(1):41-48.
[16]  Litvan I,Agid Y,Calne D,et al.Clinical research criteria for the diagnosis of progressive supranuclear palsy(Steele-Richardson-Olszewski syndrome):report of the NINDS-SPSP international workshop[J].Neurology,1996,47(1):1-9.
[17]  Nath U,Ben-Shlomo Y,Thomson RG,et al.Clinical features and natural history of progressive supranuclear palsy:a clinical cohort study[J].Neurology,2003,60(6):910-916.
[18]  Santacruz P,Uttl B,Litvan I,et al.Progressive supranuclear palsy:a survey of the disease course[J].Neurology,1998,50(6):1 637-1 647.
[19]  Goetz CG,Leurgans S,Lang AE,et al.Progression of gait,speech and swallowing deficits in progressive supranuclear palsy[J].Neurology,2003,60(6):917-922.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133